MRNA
Moderna, Inc. · Healthcare · Biotechnology
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 2 | 0 | 94.02K | $17.71M | n/a | −1 |
| Q2 2026 | 145 | +2 | 263.41M | $18.44B | +8 | −7 |
| Q1 2026 | 147 | +3 | 253.55M | $12.87B | +6 | −4 |
| Q4 2025 | 144 | +3 | 257.18M | $7.59B | +5 | −1 |
| Q3 2025 | 18 | +1 | 165.07M | $4.26B | +2 | −2 |
| Q2 2025 | 15 | 0 | 160.48M | $4.43B | +1 | −1 |
| Q1 2025 | 12 | -2 | 69.84M | $1.98B | +1 | −3 |
| Q4 2024 | 14 | -1 | 78.84M | $3.28B | +3 | −4 |
| Q3 2024 | 14 | -2 | 62.86M | $4.20B | +2 | −4 |
| Q2 2024 | 16 | n/a | 65.32M | $7.75B | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Baillie Gifford ✦ | 43.45M | n/a | $5.16B | 4.0% | n/c | 1 | SEC ↗ ×4 |
| 2 | Geode Capital Management ✦ (passive) | 6.89M | n/a | $815.90M | 0.1% | n/c | 1 | SEC ↗ ×2 |
| 3 | Wellington Management ✦ | 4.32M | n/a | $512.83M | 0.1% | n/c | 1 | SEC ↗ ×6 |
| 4 | Capital World Investors ✦ | 3.67M | n/a | $435.48M | 0.1% | n/c | 1 | SEC ↗ |
| 5 | Norges Bank ✦ (passive) | 3.35M | n/a | $397.91M | 0.1% | n/c | 1 | SEC ↗ |
| 6 | T. Rowe Price ✦ | 1.60M | n/a | $189.97M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 7 | ARK Investment Management ✦ | 1.05M | n/a | $125.17M | 1.1% | n/c | 1 | SEC ↗ |
| 8 | Citadel Advisors ✦ | 460.46K | n/a | $54.68M | 0.1% | n/c | 1 | SEC ↗ |
| 9 | Adage Capital Partners ✦ | 252.45K | n/a | $29.98M | 0.1% | n/c | 1 | SEC ↗ |
| 10 | Renaissance Technologies ✦ | 85.90K | n/a | $10.20M | 0.0% | n/c | 1 | SEC ↗ |
| 11 | Gotham Asset Management ✦ | 67.40K | n/a | $8.00M | 0.1% | n/c | 1 | SEC ↗ |
| 12 | Millennium Management ✦ | 49.20K | n/a | $5.84M | 0.0% | n/c | 1 | SEC ↗ |
| 13 | Marshall Wace ✦ | 35.20K | n/a | $4.18M | 0.0% | n/c | 1 | SEC ↗ |
| 14 | Two Sigma Investments ✦ | 19.38K | n/a | $2.30M | 0.0% | n/c | 1 | SEC ↗ |
| 15 | Bridgewater Associates ✦ | 15.31K | n/a | $1.82M | 0.0% | n/c | 1 | SEC ↗ |
| 16 | AQR Capital Management ✦ | 5.08K | n/a | $603,586 | 0.0% | n/c | 1 | SEC ↗ ×2 |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 717 holders, 306.78M shares, $15.39B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 39.15K sh · $8.64M
Officer · 450 sh · $96,368
Officer · 38.77K sh · $8.28M
Officer · 40.28K sh · $5.88M
Officer · 40.29K sh · $5.81M
Officer · 19.84K sh · $2.67M
Officer · 15.00K sh · $2.02M
Officer · 3.47K sh · $485,766
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology